<div id="readability-page-1"><h3>President's Day Sale - 70% Off</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul>An announcement from CANbridge Pharmaceuticals Inc. ( (HK:1228) ) is now available. CANbridge Pharmaceuticals has entered into a subscription agreement to issue 84,033,613 new shares at HK$2.38 per share to a Hong Kong limited partnership indirectly wholly owned by WuXi Biologics. The pricing represents a discount to recent market prices, and the listing of these subscription shares on the Hong Kong Stock Exchange is subject to regulatory approval. The share sale is expected to raise approximately HK$199 million in net proceeds, which CANbridge plans to use for working capital and registration maintenance of commercialized products, research and development of its existing pipeline, and settlement of group trade payables. The transaction, which remains conditional on the fulfillment or waiver of certain conditions, underscores ongoing strategic financial support from a major biologics contract research and manufacturing player. The most recent analyst rating on (HK:1228) stock is a Buy with a HK$3.00 price target. To see the full list of analyst forecasts on CANbridge Pharmaceuticals Inc. stock, see the HK:1228 Stock Forecast page. More about CANbridge Pharmaceuticals Inc. CANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics, with a portfolio that includes commercialized products and a pipeline of drug candidates. The company operates in the healthcare and life sciences sector, with a focus on biopharmaceutical innovation and related research and development activities. Average Trading Volume: 3,434,975 Technical Sentiment Signal: Buy Current Market Cap: HK$1.43B For an in-depth examination of 1228 stock, go to TipRanks’ Overview page.</div>

560600

159837

588130

CANbridge Pharmaceuticals Inc. has announced a subscription agreement to issue 84,033,613 new shares at HK$2.38 each, raising approximately HK$199 million. The shares will be sold to a Hong Kong limited partnership owned by WuXi Biologics, at a discount to market prices. Proceeds will be used for working capital, R&D, and settling trade payables. The transaction is subject to regulatory approval and reflects ongoing support from WuXi Biologics. The latest analyst rating for CANbridge stock is a Buy with a target price of HK$3.00.

Tip Ranks

Founder Fubon CSI Medicine and Medical Device Innovation ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

WUXI BIO

Bosera Hang Seng SCHK Innovative Drug Select ETF

Yinhua CSI Innovative Drugs Industry ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

China Southern Hang Seng Biotech ETF(QDII)

Penghua SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Penghua CSI HK Connect Health Care Composite ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

Tianhong CNI BIOMEDICINE ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Bosera Hang Seng Health Care ETF(QDII)

E Fund CSI 300 Health Care ETF

WuXi Biologics

CANBRIDGE-B

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

CANbridge to Raise HK$199 Million via Discounted Share Subscription Backed by WuXi Biologics Unit